Zuco, Valentina
Pasquali, Sandro
Tortoreto, Monica
Brich, Silvia
Percio, Stefano
Dagrada, Gian Paolo
Colombo, Chiara
Sanfilippo, Roberta
Lauricella, Calogero
Gounder, Mrinal
El Bezawy, Rihan
Barisella, Marta
Dei Tos, Angelo Paolo
Casali, Paolo Giovanni
Gronchi, Alessandro
Stacchiotti, Silvia
Zaffaroni, Nadia
Funding for this research was provided by:
Ministero della Salute
Article History
Received: 23 November 2020
Accepted: 17 February 2021
First Online: 1 March 2021
Ethics approval and consent to participate
: The study was authorized by the Ethics Committee of the Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy (Project approval code: INT 131/16). All patients provided written informed consent. Animal experiments were authorized by the Italian Ministry of Health according to the national law (Project approval code: 234/2018-PR).
: Not applicable.
: R. S. received institutional research funding from Karyopharm. M.G. had research grants and personal fees from Karyopharm. P.G.C. received institutional research funding from Karyopharm. S.S. had advisory role in Karyopharm and received institutional research funding from Karyopharm. All the remaining authors have no conflicts of interest to declare. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.